Print
DEALS:
Pharma to Support Early-Stage BiotechsRoche and Bayer team with QB3 while Atlas Ventures rounds up Amgen and Novartis.
As Big Pharma continues to externalize its early stage R&D, it is ramping up its efforts to tap early stage innovation and support biotech startups that may eventually help fill its pipeline. Both Roche and Bayer announced that they will work with startup accelerator California Institute for Quantitative Biosciences, or QB3, to help identify, fund, and support early stage life science companies in the San Francisco Bay area. QB3 was established to create companies based on research conducted at the Universities of California Berkeley, San Francisco, and Santa Cruz. Read More
Business Models
Elan Buys Stake in Theravance Royalties on DrugsDeal gives Irish company a 21 percent stake in future payments associated with four respiratory programs. Read More.Deals
Life Sciences IPOs AccelerateQuintiles upsizes offering to $947 million. Read More.Initial Public Offerings
Spate of Life Science IPOs Ready to DebutQuintiles $750 million offering could cap a busy week. Read More.Deals
Ambrx Strikes Deal with Bristol-Myers for ADC TechnologyBiotech’s new agreement is third collaboration in less than three years. Read More.Investment Funds
Capital Royalty Raises $805 Million FundFirm says investible capital to exceed $1 billion in fund. Read More.Venture Capital
Natera Lands $54.6 Million to Tranform Pre-Natal TestingCompany will use funds to advance roll-out of low-risk genetic test. Read More.Investment Funds
Atlas Ventures Closes $265 Million FundLatest in a string of venture funds focused on seed and early-stage biotechs. Read More.Initial Public Offerings
Regulus CEO Praises JOBS ActDespite weak debut, Xanthopoulos sees big benefits in new law. Read More.Deals
Ocera Therapeutics Going Public in Merger with TranzymeDeal includes $20 million PIPE financing from Ocera’s backers. Read More.Early-Stage Finance
GSK Teams with Avalon to Fund San Diego BiotechsPharma partners with venture capital to launch up to ten early-stage life companies. Read More.Mergers and Acquisitions
Thermo Fisher Acquires Life Tech for $13.6BStrategic buyer beats out private equity consortium to become leading life sciences tools and technology provider. Read More.Mergers and Acquisitions
Royalty Pharma Moves to Acquire ElanDeal in jeopardy as drugmaker goes ahead with $1 billion return to shareholders. Read More.Deals
Allecra Debuts with $19.5 Million in FundingNew company is focused on antibiotics for multi-drug-resistant infections. Read More.Deals
Chimerix and Omthera Go Public in Upsized OfferingsOne company prices in its target range, the other at a significant discount. Read More.Research and Development
VistaGen Secures $36 MillionEuropean investor provides funds to accelerate drug rescue programs. Read More.
.gif)
.png){kind=small} |
 |